RLYB Stock Catalyst: Recursion Pharmaceuticals Acquires Full Rights to REV102 from Rallybio Corp

Recursion Pharmaceuticals has acquired full rights to REV102, a potential first-in-class oral ENPP1 inhibitor for hypophosphatasia, from Rallybio Corp. The acquisition includes an upfront payment of $7.5 million and potential future milestone payments totaling $12.5 million. Recursion will also pay $5 million in low single-digit royalties.

Rallybio Corp has 20,316,700 shares in free float and 42,243,800 shares outstanding.

This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.